title: Newer insights into cisplatin nephrotoxicity.
abstract: OBJECTIVE
  To review recent advances in the understanding of the mechanisms of cisplatin nephrotoxicity. Factors affecting this toxicity and agents that may protect against it are discussed.
  
  
  METHODS
  A MEDLINE search was used to identify pertinent literature including reviews. A manual search of bibliographies was performed to include all articles on the subject.
  
  
  METHODS
  All available data relating to the mechanisms, modifying factors, and management of cisplatin nephrotoxicity were assessed.
  
  
  METHODS
  As limited human data are available, all animal studies were included. Articles with hypotheses or suggestions not backed by scientific data were excluded from review.
  
  
  RESULTS
  Cisplatin is one of the most effective agents available for treating a variety of solid tumors. Nephrotoxicity is the dose-limiting factor for the use of this drug. Mechanisms for renal toxicity range from definitive histologic changes found in the proximal convoluted tubules to physiologic and biochemical alterations involving a decrease in mitochondrial respiratory function, enzymatic activity in the respiratory chain and glutathione peroxidase, and effects on cellular calcium homeostasis. Important factors related to nephrotoxicity include age, renal irradiation, and concurrent alcohol intake. Agents that appear promising in attenuating the nephrotoxic effects of cisplatin include loading with NaCl solution and/or mannitol, sodium thiosulfate, WR 2721, glutathione, probenecid, and many other compounds under active investigation.
  
  
  CONCLUSIONS
  Cisplatin is a nephrotoxic drug; however, agents that may make cisplatin therapy more safe and rewarding will be available in the near future.
authors.affiliation: Department of Medicine, New England Deaconess Hospital, Harvard Medical School, Boston, MA 02215.
authors.forename: A J
authors.initials: AJ
authors.lastname: Anand
authors.forename: B
authors.initials: B
authors.lastname: Bashey
mesh_terms: D004999:Amifostine / Q000627:therapeutic use; D000818:Animals; D002945:Cisplatin / Q000009:adverse effects* / Q000037:antagonists & inhibitors; D005665:Furosemide / Q000627:therapeutic use; D005978:Glutathione / Q000627:therapeutic use; D006801:Humans; D007674:Kidney Diseases / Q000139:chemically induced* / Q000517:prevention & control; D008297:Male; D008353:Mannitol / Q000627:therapeutic use; D012965:Sodium Chloride / Q000627:therapeutic use; D013885:Thiosulfates / Q000627:therapeutic use
chemical_list: D013885:Thiosulfates; D008353:Mannitol; D012965:Sodium Chloride; D005665:Furosemide; D005978:Glutathione; C017717:sodium thiosulfate; D004999:Amifostine; D002945:Cisplatin